{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:25:30Z","timestamp":1790461530778,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Orthopedic Clinics of North America"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.ocl.2022.06.001","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T01:15:46Z","timestamp":1663118146000},"page":"361-375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Opioid-Related Genetic Polymorphisms of Cytochrome P450 Enzymes after Total Joint Arthroplasty"],"prefix":"10.1016","volume":"53","author":[{"given":"Brendan J.","family":"Farley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed E.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali S.","family":"Esseili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hruska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamal","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled J.","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ocl.2022.06.001_bib1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.5435\/JAAOS-D-14-00163","article-title":"The opioid epidemic: impact on orthopaedic surgery","volume":"23","author":"Morris","year":"2015","journal-title":"J\u00a0Am Acad Orthop Surg"},{"issue":"3 Suppl","key":"10.1016\/j.ocl.2022.06.001_bib2","doi-asserted-by":"crossref","first-page":"Es9","DOI":"10.36076\/ppj.2012\/15\/ES9","article-title":"Opioid epidemic in the United States","volume":"15","author":"Manchikanti","year":"2012","journal-title":"Pain Physician"},{"issue":"3","key":"10.1016\/j.ocl.2022.06.001_bib3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/AJP.0b013e3181ff04ca","article-title":"Economic costs of nonmedical use of prescription opioids","volume":"27","author":"Hansen","year":"2011","journal-title":"Clin J Pain"},{"issue":"8","key":"10.1016\/j.ocl.2022.06.001_bib4","first-page":"774","article-title":"CDC Grand Rounds: Prescription Drug Overdoses\u2014a U.S. Epidemic","volume":"307","year":"2012","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ocl.2022.06.001_bib5","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.2106\/JBJS.RVW.17.00184","article-title":"Pharmacogenomics Testing for Postoperative Pain Optimization Before Total Knee and Total Hip Arthroplasty","volume":"6","author":"Awad","year":"2018","journal-title":"JBJS Rev"},{"issue":"1","key":"10.1016\/j.ocl.2022.06.001_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s42836-019-0007-3","article-title":"Patient satisfaction and total hip arthroplasty: a review","volume":"1","author":"Okafor","year":"2019","journal-title":"Arthroplasty"},{"issue":"12","key":"10.1016\/j.ocl.2022.06.001_bib7","doi-asserted-by":"crossref","first-page":"e0167911","DOI":"10.1371\/journal.pone.0167911","article-title":"Patients\u2019 Expectations Impact Their Satisfaction following Total Hip or Knee Arthroplasty","volume":"11","author":"Neuprez","year":"2016","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.ocl.2022.06.001_bib8","first-page":"893","article-title":"The role of pain and function in determining patient satisfaction after total knee replacement","volume":"89-B","author":"Baker","year":"2007","journal-title":"The Journal of Bone and Joint Surgery. British volume"},{"issue":"5","key":"10.1016\/j.ocl.2022.06.001_bib9","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.2106\/JBJS.RVW.18.00058","article-title":"Pharmacogenomic Testing for Postoperative Pain Optimization Before Total Joint Arthroplasty: A Focus on Drug-Drug-Gene Interaction with Commonly Prescribed Drugs and Prior Opioid Use","volume":"7","author":"Awad","year":"2019","journal-title":"JBJS Rev"},{"issue":"7","key":"10.1016\/j.ocl.2022.06.001_bib10","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0025-6196(11)60750-7","article-title":"Opioid metabolism","volume":"84","author":"Smith","year":"2009","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.ocl.2022.06.001_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40122-017-0069-2","article-title":"Genetic testing for opioid pain management: a primer","volume":"6","author":"Agarwal","year":"2017","journal-title":"Pain Ther"},{"key":"10.1016\/j.ocl.2022.06.001_bib12","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/0897190007304821","article-title":"Pharmacogenetics of the Cytochrome P450 Enzyme System: Review of Current Knowledge and Clinical Significance","volume":"20","author":"Al-Omari","year":"2007","journal-title":"J\u00a0Pharm Pract"},{"issue":"10","key":"10.1016\/j.ocl.2022.06.001_bib13","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.tig.2015.05.010","article-title":"Human Structural Variation: Mechanisms of Chromosome Rearrangements","volume":"31","author":"Weckselblatt","year":"2015","journal-title":"Trends Genet"},{"issue":"507","key":"10.1016\/j.ocl.2022.06.001_bib14","article-title":"Exploring the Impact of Single-Nucleotide Polymorphisms on Translation","volume":"9","author":"Robert","year":"2018","journal-title":"Front Genet"},{"issue":"7","key":"10.1016\/j.ocl.2022.06.001_bib15","first-page":"412","article-title":"Pharmacogenomics in clinical practice: reality and expectations","volume":"36","author":"Ventola","year":"2011","journal-title":"P\u00a0t"},{"issue":"1","key":"10.1016\/j.ocl.2022.06.001_bib16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.ocl.2022.06.001_bib18","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ocl.2022.06.001_bib19","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ymgme.2009.08.009","article-title":"Identification of genetic variants of human cytochrome P450 2D6 with impaired mitochondrial targeting","volume":"99","author":"Sangar","year":"2010","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1016\/j.ocl.2022.06.001_bib20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00228-011-1093-5","article-title":"Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study","volume":"68","author":"Andreassen","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.ocl.2022.06.001_bib21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/FTD.0b013e3182272b10","article-title":"CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study","volume":"33","author":"VanderVaart","year":"2011","journal-title":"Ther Drug Monit"},{"issue":"7","key":"10.1016\/j.ocl.2022.06.001_bib22","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.pnpbp.2006.03.018","article-title":"Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer","volume":"30","author":"Susce","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"6","key":"10.1016\/j.ocl.2022.06.001_bib23","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.clpt.2004.08.020","article-title":"Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension","volume":"76","author":"Zineh","year":"2004","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.ocl.2022.06.001_bib24","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/01.jcp.0000085421.74359.60","article-title":"Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers","volume":"23","author":"de Leon","year":"2003","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"8","key":"10.1016\/j.ocl.2022.06.001_bib25","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00228-011-1080-x","article-title":"Near-fatal tramadol cardiotoxicity in a CYP2D6 ultrarapid metabolizer","volume":"67","author":"Elkalioubie","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.ocl.2022.06.001_bib26","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1213\/ane.0b013e31817b796e","article-title":"Respiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplication","volume":"107","author":"Stamer","year":"2008","journal-title":"Anesth Analg"},{"issue":"8","key":"10.1016\/j.ocl.2022.06.001_bib27","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00228-009-0640-9","article-title":"O-demethylation of codeine to morphine inhibited by low-dose levomepromazine","volume":"65","author":"Vevelstad","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ocl.2022.06.001_bib28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1213\/ANE.0b013e31825b6824","article-title":"Trends in in-hospital major morbidity and mortality after total joint arthroplasty: United States 1998-2008","volume":"115","author":"Kirksey","year":"2012","journal-title":"Anesth Analg"},{"issue":"6 Suppl 1","key":"10.1016\/j.ocl.2022.06.001_bib29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.arth.2008.05.011","article-title":"In hospital complications after total joint arthroplasty","volume":"23","author":"Pulido","year":"2008","journal-title":"J\u00a0Arthroplasty"},{"issue":"24","key":"10.1016\/j.ocl.2022.06.001_bib30","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.2106\/JBJS.N.00153","article-title":"Postoperative myocardial infarction and cardiac arrest following primary total knee and hip arthroplasty: rates, risk factors, and time of occurrence","volume":"96","author":"Belmont","year":"2014","journal-title":"J\u00a0Bone Joint Surg Am"},{"issue":"7","key":"10.1016\/j.ocl.2022.06.001_bib31","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0002-9343(03)00474-1","article-title":"Association between cardiac and noncardiac complications in patients undergoing noncardiac surgery: outcomes and effects on length of stay","volume":"115","author":"Fleischmann","year":"2003","journal-title":"Am J Med"},{"issue":"9 Suppl","key":"10.1016\/j.ocl.2022.06.001_bib32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.arth.2015.01.057","article-title":"Can the American College of Surgeons Risk Calculator Predict 30-Day Complications After Knee and Hip Arthroplasty?","volume":"30","author":"Edelstein","year":"2015","journal-title":"J\u00a0Arthroplasty"},{"issue":"17","key":"10.1016\/j.ocl.2022.06.001_bib33","first-page":"e418","volume":"116","author":"Fleisher","year":"2007","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ocl.2022.06.001_bib34","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/ALN.0b013e3181b6a761","article-title":"Effect of beta-blocker prescription on the incidence of postoperative myocardial infarction after hip and knee arthroplasty","volume":"111","author":"van Klei","year":"2009","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.ocl.2022.06.001_bib35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/clpt.2008.172","article-title":"Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users","volume":"85","author":"Bijl","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.ocl.2022.06.001_bib36","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1056\/NEJMc0904266","article-title":"Codeine, ultrarapid-metabolism genotype, and postoperative death","volume":"361","author":"Ciszkowski","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ocl.2022.06.001_bib37","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/clpt.2013.193","article-title":"An investigation of CYP2D6 genotype and response to metoprolol CR\/XL during dose titration in patients with heart failure: a MERIT-HF substudy","volume":"95","author":"Batty","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ocl.2022.06.001_bib38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/clpt.2014.62","article-title":"Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate","volume":"96","author":"Hamadeh","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.ocl.2022.06.001_bib39","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00228-009-0646-3","article-title":"The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease","volume":"65","author":"Shord","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"issue":"1\u20132","key":"10.1016\/j.ocl.2022.06.001_bib40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pain.2009.03.023","article-title":"Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?","volume":"144","author":"Lotsch","year":"2009","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.ocl.2022.06.001_bib41","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1248\/bpb.30.537","article-title":"Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis","volume":"30","author":"Takekuma","year":"2007","journal-title":"Biol Pharm Bull"},{"issue":"4","key":"10.1016\/j.ocl.2022.06.001_bib42","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2125.2007.03052.x","article-title":"Influence of the CYP2D6\u22174 polymorphism on dose, switching and discontinuation of antidepressants","volume":"65","author":"Bijl","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ocl.2022.06.001_bib43","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/13651500902903016","article-title":"Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms","volume":"13","author":"Van Nieuwerburgh","year":"2009","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"Pt 6","key":"10.1016\/j.ocl.2022.06.001_bib44","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1258\/acb.2009.009003","article-title":"Depressive effect of an antidepressant: therapeutic failure of venlafaxine in a case lacking CYP2D6 activity","volume":"46","author":"Wijnen","year":"2009","journal-title":"Ann Clin Biochem"},{"issue":"2","key":"10.1016\/j.ocl.2022.06.001_bib45","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2753.2008.01001.x","article-title":"Post-operative anxiety and depression levels in orthopaedic surgery: a study of 56 patients undergoing hip or knee arthroplasty","volume":"15","author":"Nickinson","year":"2009","journal-title":"J\u00a0Eval Clin Pract"},{"issue":"12","key":"10.1016\/j.ocl.2022.06.001_bib46","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1080\/13607863.2015.1072801","article-title":"Depression and anxiety after total joint replacement among older adults: a meta-analysis","volume":"20","author":"Scott","year":"2016","journal-title":"Aging Ment Health"},{"issue":"1","key":"10.1016\/j.ocl.2022.06.001_bib47","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/0091270010394852","article-title":"Efficacy of antidepressants as analgesics: a review","volume":"52","author":"Dharmshaktu","year":"2012","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.ocl.2022.06.001_bib48","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/tpj.2010.39","article-title":"Association between CYP2C19\u221717 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients","volume":"11","author":"de Vos","year":"2011","journal-title":"Pharmacogenomics J"},{"issue":"3","key":"10.1016\/j.ocl.2022.06.001_bib49","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s13181-011-0158-2","article-title":"Prolonged toxicity after amitriptyline overdose in a patient deficient in CYP2D6 activity","volume":"7","author":"Smith","year":"2011","journal-title":"J\u00a0Med Toxicol"},{"issue":"2","key":"10.1016\/j.ocl.2022.06.001_bib50","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/FPC.0000000000000113","article-title":"PharmGKB summary: ibuprofen pathways","volume":"25","author":"Mazaleuskaya","year":"2015","journal-title":"Pharmacogenet Genomics"},{"issue":"11","key":"10.1016\/j.ocl.2022.06.001_bib51","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2106\/JBJS.J.01095","article-title":"Multimodal pain management after total joint arthroplasty","volume":"93","author":"Parvizi","year":"2011","journal-title":"J\u00a0Bone Joint Surg Am"},{"issue":"2","key":"10.1016\/j.ocl.2022.06.001_bib52","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.arth.2012.04.008","article-title":"Perioperative administration of selective cyclooxygenase-2 inhibitors for postoperative pain management in patients after total knee arthroplasty","volume":"28","author":"Lin","year":"2013","journal-title":"J\u00a0Arthroplasty"},{"issue":"3","key":"10.1016\/j.ocl.2022.06.001_bib53","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/tpj.2013.28","article-title":"Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain","volume":"14","author":"Llerena","year":"2014","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"10.1016\/j.ocl.2022.06.001_bib54","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1053\/j.gastro.2007.05.025","article-title":"Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms","volume":"133","author":"Pilotto","year":"2007","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.ocl.2022.06.001_bib55","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/jcph.169","article-title":"Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib","volume":"53","author":"Prieto-Perez","year":"2013","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.ocl.2022.06.001_bib56","doi-asserted-by":"crossref","first-page":"683","DOI":"10.5414\/CP201467","article-title":"Effects of CYP2C9\u22171\/\u22173 and \u22171\/\u221713 on the pharmacokinetics of losartan and its active metabolite E-3174","volume":"50","author":"Bae","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.ocl.2022.06.001_bib57","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11239-012-0725-7","article-title":"Impact of CYP2C9\u22173, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients","volume":"34","author":"Liang","year":"2012","journal-title":"J\u00a0Thromb Thrombolysis"},{"issue":"9984","key":"10.1016\/j.ocl.2022.06.001_bib58","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(14)61994-2","article-title":"Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial","volume":"385","author":"Mega","year":"2015","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ocl.2022.06.001_bib59","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3346\/jkms.2014.29.9.1317","article-title":"Extremely elevated international normalized ratio of warfarin in a patient with CYP2C9\u22171\/\u22173 and thyrotoxicosis","volume":"29","author":"Lee","year":"2014","journal-title":"J\u00a0Korean Med Sci"},{"issue":"2","key":"10.1016\/j.ocl.2022.06.001_bib60","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/FPC.0b013e32831a9ae3","article-title":"Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement","volume":"19","author":"Kim","year":"2009","journal-title":"Pharmacogenet Genomics"},{"issue":"7","key":"10.1016\/j.ocl.2022.06.001_bib61","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2217\/pgs.12.40","article-title":"A\u00a0clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9\u22173 allele","volume":"13","author":"Andersson","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.ocl.2022.06.001_bib62","article-title":"Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis","volume":"9","author":"Dennis","year":"2014"},{"issue":"7438","key":"10.1016\/j.ocl.2022.06.001_bib63","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/bmj.328.7438.509","article-title":"Bupropion and other non-nicotine pharmacotherapies","volume":"328","author":"Roddy","year":"2004","journal-title":"Bmj"},{"issue":"9","key":"10.1016\/j.ocl.2022.06.001_bib64","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s00228-015-1896-x","article-title":"CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy","volume":"71","author":"Tomaz","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.ocl.2022.06.001_bib65","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1369-1600.2011.00349.x","article-title":"CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction","volume":"18","author":"Levran","year":"2013","journal-title":"Addict Biol"},{"issue":"6","key":"10.1016\/j.ocl.2022.06.001_bib66","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1213\/ANE.0b013e3181bdc8a0","article-title":"The early and delayed analgesic effects of ketamine after total hip arthroplasty: a prospective, randomized, controlled, double-blind study","volume":"109","author":"Remerand","year":"2009","journal-title":"Anesth Analg"},{"issue":"2","key":"10.1016\/j.ocl.2022.06.001_bib67","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1213\/01.ANE.0000142117.82241.DC","article-title":"Small dose ketamine improves postoperative analgesia and rehabilitation after total knee arthroplasty","volume":"100","author":"Adam","year":"2005","journal-title":"Anesth Analg"},{"issue":"2","key":"10.1016\/j.ocl.2022.06.001_bib68","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/bcp.12614","article-title":"CYP2B6\u22176 allele and age substantially reduce steady-state ketamine clearance in chronic pain patients: impact on adverse effects","volume":"80","author":"Li","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ocl.2022.06.001_bib69","first-page":"242","article-title":"CYP2B6 genotype guided dosing of propofol anesthesia in the elderly based on nonparametric population pharmacokinetic modeling and simulations","volume":"6","author":"Eugene","year":"2017","journal-title":"Int J Clin Pharmacol Toxicol"},{"issue":"4","key":"10.1016\/j.ocl.2022.06.001_bib70","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00228-011-1132-2","article-title":"Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia","volume":"68","author":"Loryan","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ocl.2022.06.001_bib71","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/00000542-200602000-00023","article-title":"Perioperative abstinence from cigarettes: physiologic and clinical consequences","volume":"104","author":"Warner","year":"2006","journal-title":"Anesthesiology"},{"issue":"1 Supple A","key":"10.1016\/j.ocl.2022.06.001_bib72","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1302\/0301-620X.100B1.BJJ-2017-0547.R1","article-title":"Trends and risk factors for prolonged opioid use after unicompartmental knee arthroplasty","volume":"100-b","author":"Bedard","year":"2018","journal-title":"Bone Joint J"},{"issue":"4","key":"10.1016\/j.ocl.2022.06.001_bib73","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.clpt.2006.06.011","article-title":"Determinants of the rate of nicotine metabolism and effects on smoking behavior","volume":"80","author":"Johnstone","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.ocl.2022.06.001_bib74","first-page":"1175","article-title":"Twenty years of biochemistry of human P450s: purification, expression, mechanism, and relevance to drugs","volume":"26","author":"Guengerich","year":"1998","journal-title":"Drug Metab Dispos"},{"issue":"1\u20133","key":"10.1016\/j.ocl.2022.06.001_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0300-483X(95)03155-9","article-title":"Substrates of human hepatic cytochrome P450 3A4","volume":"104","author":"Li","year":"1995","journal-title":"Toxicology"},{"issue":"10","key":"10.1016\/j.ocl.2022.06.001_bib76","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1172\/JCI119439","article-title":"Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression","volume":"99","author":"Lown","year":"1997","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.ocl.2022.06.001_bib77","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000258688","article-title":"CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease","volume":"31","author":"Bhatnagar","year":"2010","journal-title":"Am J Nephrol"},{"issue":"3","key":"10.1016\/j.ocl.2022.06.001_bib78","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/clpt.2014.129","article-title":"Functional gene variants of CYP3A4","volume":"96","author":"Werk","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.ocl.2022.06.001_bib79","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/FPC.0000000000000079","article-title":"CYP3A4\u221722 and CYP3A5\u22173 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort","volume":"24","author":"Kitzmiller","year":"2014","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"10.1016\/j.ocl.2022.06.001_bib80","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00007890-199607150-00023","article-title":"Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients","volume":"62","author":"Min","year":"1996","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.ocl.2022.06.001_bib81","doi-asserted-by":"crossref","first-page":"e0127995","DOI":"10.1371\/journal.pone.0127995","article-title":"Effects of the CYP3A4\u22171B Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Adult Renal Transplant Recipients: A Meta-Analysis","volume":"10","author":"Shi","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.ocl.2022.06.001_bib82","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/bdd.2078","article-title":"Inactivation kinetics and residual activity of CYP3A4 after treatment with erythromycin","volume":"38","author":"Ishikawa","year":"2017","journal-title":"Biopharm Drug Dispos"},{"issue":"6","key":"10.1016\/j.ocl.2022.06.001_bib83","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1124\/dmd.110.032094","article-title":"Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation","volume":"38","author":"Foti","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.ocl.2022.06.001_bib84","first-page":"167","article-title":"Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation","volume":"82","author":"Tateishi","year":"1996","journal-title":"Anesth Analg"},{"issue":"9","key":"10.1016\/j.ocl.2022.06.001_bib85","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.cca.2010.12.038","article-title":"Impact of CYP3A4\u22171G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery","volume":"412","author":"Yuan","year":"2011","journal-title":"Clinica Chim Acta"},{"issue":"4","key":"10.1016\/j.ocl.2022.06.001_bib86","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/10408363.2011.620601","article-title":"Methadone: a review of drug-drug and pathophysiological interactions","volume":"48","author":"Kapur","year":"2011","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"10","key":"10.1016\/j.ocl.2022.06.001_bib87","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2217\/pgs.11.103","article-title":"Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients","volume":"12","author":"Chen","year":"2011","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.ocl.2022.06.001_bib88","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1053\/pcad.2001.29096","article-title":"Calcium channel blockers in treatment of hypertension","volume":"44","author":"Muntwyler","year":"2001","journal-title":"Prog Cardiovasc Dis"},{"issue":"9","key":"10.1016\/j.ocl.2022.06.001_bib89","doi-asserted-by":"crossref","first-page":"737","DOI":"10.5414\/CP202211","article-title":"Effect of CYP3A4\u22171G, CYP3A5\u22173, POR\u221728, and ABCB1 C3435T on the pharmacokinetics of nifedipine in healthy Chinese volunteers","volume":"53","author":"Wang","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.ocl.2022.06.001_bib90","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00228-008-0502-x","article-title":"CYP3A4\u22171G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin","volume":"64","author":"Gao","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ocl.2022.06.001_bib91","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s13318-016-0324-7","article-title":"Impact of CYP3A4\u22171G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel","volume":"42","author":"Danielak","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"12","key":"10.1016\/j.ocl.2022.06.001_bib92","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/ejhg.2016.114","article-title":"Role of pharmacogenetics in public health and clinical health care: a SWOT analysis","volume":"24","author":"Kapoor","year":"2016","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"10.1016\/j.ocl.2022.06.001_bib93","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/187569212800626430","article-title":"Pharmacogenomics in Primary Care: A Crucial Entry Point for Global Personalized Medicine?","volume":"10","author":"Bartlett","year":"2012","journal-title":"Curr Pharmacogenomics Person Med"},{"issue":"13","key":"10.1016\/j.ocl.2022.06.001_bib94","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMra1507771","article-title":"Opioid abuse in chronic pain--misconceptions and mitigation strategies","volume":"374","author":"Volkow","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ocl.2022.06.001_bib95","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/2049463713507439","article-title":"Pharmacogenetics of analgesic drugs","volume":"7","author":"Cregg","year":"2013","journal-title":"Br J Pain"},{"issue":"7","key":"10.1016\/j.ocl.2022.06.001_bib96","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1515\/CCLM.2011.181","article-title":"Molecular diagnostics for pharmacogenomic testing of fluoropyrimidine based-therapy: costs, methods and applications","volume":"49","author":"Di Francia","year":"2011","journal-title":"Clin Chem Lab Med"}],"container-title":["Orthopedic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030589822000852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030589822000852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T14:49:08Z","timestamp":1758466148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0030589822000852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":95,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0030589822000852"],"URL":"https:\/\/doi.org\/10.1016\/j.ocl.2022.06.001","relation":{},"ISSN":["0030-5898"],"issn-type":[{"value":"0030-5898","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opioid-Related Genetic Polymorphisms of Cytochrome P450 Enzymes after Total Joint Arthroplasty","name":"articletitle","label":"Article Title"},{"value":"Orthopedic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ocl.2022.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}